Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Grant #051794 |
Not provided
Not provided
Not provided
We were unable to recruit sufficient numbers of patients and decided that the study protocol was not feasible to implement
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Robert Wood Johnson Foundation | OTHER |
The purpose of this small preliminary study is to determine whether it is feasible to recruit women smokers who have just delivered a baby and are not breastfeeding into a study that would test whether starting bupropion, a smoking cessation medication, after a baby's birth helps a postpartum woman to stop smoking.
Purpose: A pilot randomized double-blind placebo-controlled trial is testing the feasibility of conducting a full-scale trial of the efficacy of bupropion SR vs. placebo in non-breastfeeding postpartum women who smoked >1 cigarette in the last month of pregnancy and want to stop smoking. The study will estimate achievable enrollment and retention rates; estimate the effect size of the drug on tobacco abstinence; assess the tolerability of bupropion in postpartum women; and allow refinement of recruitment, retention, intervention, and assessment protocols.
Research Design: Pilot double-blind placebo-controlled randomized clinical trial.
Study Population: 40 postpartum women aged 18 years or older who smoked > 1 cigarette in the last month of pregnancy, want to stop smoking, and are not breastfeeding. Subjects will be recruited postpartum while hospitalized after delivery.
Intervention: Bupropion SR (or matching placebo) for 8 weeks, starting immediately post-delivery. The dose is 150 mg qd for one week then 150 mg bid for 7 weeks. All subjects will receive behavioral counseling delivered face-to-face during the post-delivery hospitalization and by telephone 4 times over 8 weeks.
Outcome Measures: (assessed at 2, 4, 8, and 12 weeks postpartum):
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Sugar pill |
|
| Bupropion SR | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bupropion SR | Drug |
| ||
| placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of women who are eligible for the study | ||
| Proportion of eligible women who enroll in the study | ||
| Proportion of enrolled women who complete the study |
| Measure | Description | Time Frame |
|---|---|---|
| Cotinine-verified 7-day tobacco abstinence at 2 weeks | ||
| Cotinine-verified 7-day tobacco abstinence at 8 weeks | ||
| Cotinine-verified 7-day tobacco abstinence at 12 weeks |
Not provided
Inclusion Criteria:
Postpartum women who:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nancy A Rigotti, MD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | United States |
Not provided
| ID | Term |
|---|---|
| D014029 | Tobacco Use Disorder |
| D020340 | Tobacco Use Cessation |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D015438 | Health Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Symptoms of depression at 2, 8, and 12 weeks postpartum |
| Symptoms of anxiety at 2, 8, and 12 weeks postpartum |
| Adherence to study drug at 2 and 8 weeks postpartum |
| Rate of adverse effects at 2 and 8 weeks postpartum |
| D001519 | Behavior |